Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial
科研动态Nature Medicine
2026-09-24
Evorpacept blocks the CD47–signal regulatory protein α interaction, enhancing antibody-dependent cellular phagocytosis. …
原文：Nature Medicine（本页为平台整理的中文摘要，逐句对照原文核对后发布）